argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for futility following its review of data from a pre-specified interim analysis. Importantly, efgartigimod showed a favorable safety and tolerability profile, and no new safety signals were identified. “We are disappointed the studies did not meet our desired outcome and we especially empathize with patients who are living with TED and seeking new therapies for this challenging disease,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argen
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Wells Fargo & Company from $1,095.00 to $1,316.00. They now have an "overweight" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Stifel Nicolaus from $1,028.00 to $1,248.00. They now have a "buy" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its price target raised by analysts at JPMorgan Chase & Co. from $925.00 to $1,100.00. They now have an "overweight" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its price target raised by analysts at Morgan Stanley from $1,070.00 to $1,110.00. They now have an "overweight" rating on the stock.MarketBeat
- argenex (NASDAQ:ARGX) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.MarketBeat
ARGX
Earnings
- 10/30/25 - Beat
ARGX
Sec Filings
- 12/15/25 - Form 6-K
- 11/18/25 - Form 6-K
- 11/14/25 - Form SCHEDULE
- ARGX's page on the SEC website